Ramachandran, Raja <br/><br/>
Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy.  [electronic resource] 

 -  Nephrology (Carlton, Vic.)  Dec 2019 
 - 1241-1247 p.  digital 
<br/><br/> Publication Type: Journal Article; Observational Study 
<br/><br/><label>ISSN: </label>1440-1797 
<br/><br/><label>Standard No.: </label>10.1111/nep.13554  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antigens, CD19--analysis<br/>Calcineurin Inhibitors--administration & dosage<br/>Costs and Cost Analysis<br/>Dose-Response Relationship, Drug<br/>Drug Monitoring--methods<br/>Drug Resistance<br/>Female<br/>Glomerulosclerosis, Focal Segmental--complications<br/>Glucocorticoids--therapeutic use<br/>Humans<br/>Immunologic Factors--administration & dosage<br/>India<br/>Male<br/>Nephrosis, Lipoid--complications<br/>Nephrotic Syndrome--drug therapy<br/>Rituximab--administration & dosage<br/>Treatment Outcome